Distribution and Clearance Profile of AuNP-PAMAM G4-NIMOTUZUMAB Simulated by using 198AuNP-PAMAM G4-NIMOTUZUMAB

Research on gold nanoparticles as CT-Scan contrast agents has been started 3 years ago in Indonesia. Research on interaction between monoclonal antibodies, particularly nimotuzumab and the receptor EGFR / HER1 was initiated five years ago and has been used for the preparation of MRI (Magnetic Resonance Imaging) targeted contrast agent through labeling conjugate of dendrimer-nimotuzumab with gadolinium radionuclides. Synthesis of contrast agent AuNPs-PAMAM G4-nimotuzumab for diagnosis and treatment of lung cancer have been successfully carried out in PTRR and characterization results using several methods such as High Performance Liquid Chromatography (HPLC), Sodium Dodecyl Sulphate (SDS) Page Electrophoresis and Transmission Electron Microscopy (TEM) showed that the compound formed is identified as AuNPs-PAMAM G4- nimotuzumab. In this study preclinical trials of the compound AuNPs-PAMAMG4-Nimotuzumab which consist of biodistribution, clearance and autoradiography with simulation using radioactive compounds 198AuNP-PAMAM G4-nimotuzumab has been conducted. The biodistribution test results on 198AuNP-PAMAM G4-nimotuzumab showed  accumulation in some organs such as  kidneys, liver and spleen, whereas results of klirens test showed that the biological half-life of the compound was 11.77 days. Urine analysis using PD-10 column (Sephadex G25) showed that ~ 70% of the compound excreted was still in the form of AuNP-PAMAM G4-nimotuzumab. Imaging results by means of autoradiography showed that up to 48 hours after injection, radioactivity was still observed in the liver.

Keywords : CT-Scan, nanoparticle, Nimotuzumab, biodistribution, klirens